Gastroprotection in Critically Ill Patients

Introduction to Gastroprotection

The Society of Critical Care Medicine and American Society of Health-System Pharmacists explicitly state that no evidence supports the concurrent administration of sucralfate and acid suppressants for stress ulcer prophylaxis 1, 2

PPIs (omeprazole, pantoprazole) raise gastric pH by inhibiting acid secretion, which directly undermines sucralfate's mechanism of action 1, 2
Network meta-analyses comparing PPIs, H2-receptor antagonists, and sucralfate found no benefit to combining these agents 1, 2

The American College of Cardiology recommends PPIs as the first-line choice for most patients requiring gastroprotection, with a recommended dose of ≤40 mg daily of omeprazole or pantoprazole 1, 2
Patients on dual antiplatelet therapy with GI bleeding risk factors should be considered for PPIs 3, 4
Patients on oral anticoagulants with risk factors including age >75 years, history of GI bleeding, chronic NSAID/steroid use should be considered for PPIs 4
Stress ulcer prophylaxis in critically ill patients with risk factors for clinically important upper GI bleeding should use PPIs 1, 2

The American College of Cardiology and American Heart Association recommend non-CYP2C19-interfering PPIs like pantoprazole when gastroprotection is needed with clopidogrel 3
Pantoprazole is the preferred PPI when patients are on clopidogrel due to its lower CYP2C19 interaction 3, 4

Determine if gastroprotection is needed based on bleeding risk factors, and choose one agent: PPI (pantoprazole 40 mg daily or omeprazole 40 mg daily) for most patients, or sucralfate (1 g four times daily, max 4 g/day) for mechanically ventilated patients where pneumonia risk outweighs bleeding risk 1, 2, 3, 4, 5
Never combine sucralfate with PPIs, as this is pharmacologically counterproductive and unsupported by evidence 1, 2